Cooley LLP announced today that it represented Ambit Biosciences on its initial public offering. Ambit, a San Diego-based biopharmaceutical company focused on the treatment of unmet medical needs in oncology, autoimmune and inflammatory diseases, now trades on the NASDAQ Global Stock Market under the symbol “AMBI.”

The Cooley corporate securities team included partners Tom Coll and Ken Rollins and associates James Pennington, Karen Deschaine, Jon Russo, Terren O’Connor and Michael Nieto. Partner Natasha Leskovsek (Regulatory), associate Megan Arthur (Compensation and Benefits) and partners Susan Cooper Philpot and Bill Morrow (Tax) provided critical support for the offering.


Related Posts:

Leave a Reply